INTRODUCTION
============

Cancer cell metabolism is characterized by enhanced uptake and utilization of glucose, a phenomenon known as the Warburg effect. While normal cells produce energy mainly through oxidation of pyruvate in mitochondria, cancer cells predominantly produce energy via enhanced glycolysis in the cytosol, regardless of whether they are under normoxic or hypoxic conditions ([@B41]; [@B15]). Cancer cells prefer to metabolize glucose by glycolysis to support proliferation and anabolic growth. They avoid oxidative phosphorylation even in the presence of sufficient amounts of oxygen, a property first observed by Otto Warburg ([@B13]). The altered metabolism of cancer cells is connected with elevated lactate production and proton accumulation, which causes a drop in extracellular pH that promotes cancer metastasis ([@B3]). A correlation between glycolytic ATP production and tumor malignancy is reported ([@B39]).

Hexokinase catalyzes the first committed step of the glycolytic pathway, in which glucose is phosphorylated to glucose-6-phosphate with concomitant dephosphorylation of ATP. Mammalian cells have four major HK isoforms: HK1, HK2, HK3, and HK4 ([@B43]). Whereas HK1 is the most highly expressed hexokinase isoform and has no documented function in human cancer, HK2 is involved in cancer progression ([@B30]). Up-regulation of HK2 is seen in multiple human cancers ([@B9]), and HK2 is the most pivotal HK, with a direct function in the Warburg effect. HK2 is also essential for cancer growth, survival, and metastasis ([@B29]).

HK2 expression is reported to be regulated at epigenetic, transcriptional, and posttranscriptional levels. At the transcriptional level, HK2 expression is up-regulated by hypoxia-inducible factor-1α (HIF-1α) in cancer cells. The *HK2* promoter has a consensus motif for HIF-1 ([@B33]; [@B28]) and expression is enhanced by hypoxia ([@B33]; [@B28]; [@B12]; [@B14]). Thus, *HK2* is considered to be a HIF-1α target gene ([@B35]). In addition, c-Myc is reported to be involved in up-regulation of *HK2* in fibroblast growth factor--stimulated endothelial cells ([@B48]). *HK2* expression might be epigenetically regulated, because DNA methylation of an *HK2* promoter CpG island suppresses *HK2* expression by inhibiting interaction between HIF-1α and a hypoxia response element in the *HK2* promoter ([@B16]). At the posttranscriptional level, Roquin ([@B1]) and several microRNAs (miRs) such as miR-199a-5p ([@B11]), miR-4458 ([@B31]), and miR-143 ([@B9]; [@B30]) are reported to target *HK2* mRNA and down-regulate *HK2* expression. Despite these findings, the regulation of *HK2* expression in cancer cells remains elusive.

Posttranscriptional regulation of gene expression can be mediated by AU-rich elements (AREs) located in the 3′-untranslated regions (3′-UTRs) of a variety of short-lived mRNAs such as those for cytokines and proto-oncogenes ([@B37]). The destabilizing function of AREs is regulated by ARE-binding proteins ([@B38]). One of the most well-characterized ARE-binding proteins is tristetraprolin (TTP), which promotes degradation of ARE-containing transcripts ([@B6]; [@B8]; [@B22]; [@B5]). TTP inhibits cancer cell growth by inhibiting expression of cancer-related ARE-containing genes and enhancing degradation of proto-oncogene transcripts ([@B24]; [@B47]; [@B17]a,[@B17]). TTP inhibits the EMT through down-regulation of Twist1 and Snail1 ([@B46]). TTP expression is significantly decreased in various cancers ([@B4]), which may lead to abnormalities that contribute to cancer processes.

Here, we showed that TTP acted as a negative regulator of glycolysis by posttranscriptionally down-regulating *HK2* expression in cancer cells. Overexpression of TTP reduced glucose uptake, glycolysis, and growth of cancer cells. TTP did not affect the expression of HK1, but decreased HK2 expression by enhancing degradation of *HK2* mRNA. Exogenous expression of *HK2* restored glucose uptake, glycolysis, and growth of cancer cells. These novel findings suggested that TTP served as a negative regulator of HK2 in cancer cells. Considering the low levels of TTP in various cancers ([@B4]), these results suggested a mechanism for up-regulation of HK2 observed in human cancers.

RESULTS
=======

TTP expression decreases the glycolytic capacity of cancer cells
----------------------------------------------------------------

We previously reported that TTP overexpression decreases mitochondrial potential and ATP production in cancer cells ([@B40]). We investigated whether TTP expression affected the glycolytic capacity of cancer cells. MDAMB231 and H1299 cells were transfected with pcDNA6/V5-TTP (MDAMB231/TTP and H1299/TTP) or control pcDNA6/V5 vector (MDAMB231/pcDNA and H1299/pcDNA) to overexpress TTP. Cells were analyzed for glycolytic capacity. TTP overexpression in MDAMB231 or H1299 cells ([Figure 1A](#F1){ref-type="fig"}) decreased glucose uptake ([Figure 1B](#F1){ref-type="fig"}) and production of pyruvate ([Figure 1C](#F1){ref-type="fig"}) and lactate ([Figure 1D](#F1){ref-type="fig"}). We determined the effects of TTP inhibition on glycolytic capacity. MCF-7 and A549 cells were transfected with small interfering RNA (siRNA) against *TTP* (MCF-7/TTP-siRNA and A549/TTP-siRNA) or scramble control siRNA (MCF-7/scRNA and A549/scRNA) and analyzed for glucose uptake and pyruvate and lactate production. Inhibition of *TTP* by siRNA ([Figure 2A](#F2){ref-type="fig"}) increased glucose uptake ([Figure 2B](#F2){ref-type="fig"}) and production of pyruvate ([Figure 2C](#F2){ref-type="fig"}) and lactate ([Figure 2D](#F2){ref-type="fig"}). Taken together, these results indicated that TTP negatively regulated the glycolytic capacity of cancer cells.

![TTP overexpression decreases glycolytic capacity of cancer cells. MDAMB231 and H1299 cells were transiently transfected with 1 μg pcDNA6/V5-TTP (MDAMB231/TTP and H1299/TTP) or empty vector pcDNA6/V5 (MDAMB231/pcDNA and H1299/pcDNA) for 24 h. (A) TTP level was determined by semi-qRT-PCR (top) and Western blot (bottom). Cells were analyzed for (B) glucose uptake, (C) pyruvate production, and (D) lactate production. Data represent three experiments and are mean *±* SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](mbc-30-542-g001){#F1}

![Inhibition of TTP by siRNA increases glycolytic capacity in cancer cells. MCF-7 and A549 cells were transfected with 60 pmol of TTP-specific siRNA (MCF-7/TTP-siRNA and A549/TTP-siRNA) or scRNA (MCF-7/scRNA and A549/scRNA) for 24 h. (A) TTP level was determined by semi-qRT-PCR (top) and Western blot (bottom). Cells were analyzed for (B) glucose uptake, (C) pyruvate production, and (D) lactate production. Data represent three experiments and are mean *±* SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](mbc-30-542-g002){#F2}

TTP decreases expression of HK2 in cancer cells
-----------------------------------------------

TTP might inhibit the glycolytic capacity of cancer cells by down-regulating the expression of genes encoding enzymes in the glycolytic pathway. To test this hypothesis, we used reverse transcription PCR (RT-PCR) to determine the effect of overexpression or inhibition of TTP on expression of genes in the glycolytic pathway: *GLUT1*, *HK1*, *HK2*, *PKM2*, and *LDHA*. Among the five genes, TTP overexpression decreased only *HK2* in both MDAMB231 and H1299 cells ([Figure 3A](#F3){ref-type="fig"}). The inhibition of *TTP* by siRNA increased expression of *HK2* and *LDHA* among the five genes tested in both MCF-7 and A549 cells ([Figure 3B](#F3){ref-type="fig"}). We determined the effect of TTP overexpression on mRNA degradation of the five genes. TTP overexpression did not affect the mRNA stability of *GLUT1*, *HK1*, *PKM2*, and *LDHA* ([Figure 3C](#F3){ref-type="fig"}), but enhanced degradation of *HK2* mRNA ([Figure 3D](#F3){ref-type="fig"}) in both MDAMB23 and H1299 cells. These results indicated that TTP decreased HK2 expression by enhancing degradation of *HK2* mRNA. Previously, it has been reported that *HK2* mRNA stability is regulated by BAG3, Roquin, and Imp3 in cancer cells ([@B1]). We thus tested whether TTP enhances *HK2* mRNA degradation by modulating the expression of these molecules. As shown in [Figure 3E](#F3){ref-type="fig"}, overexpression or inhibition of TTP did not affect the expression levels of these molecules in either MDAMB231 or H1299 cells. These results suggest that these molecules are not involved in TTP-mediated degradation of *HK2* mRNA in cancer cells.

![TTP enhances decay of *HK2* mRNA and reduces *HK2* expression in cancer cells. (A) TTP overexpression reduces *HK2* expression in cancer cells. MDAMB231 and H1299 cells were transiently transfected with pcDNA6/V5-TTP or pcDNA6/V5 for 24 h. Cells were analyzed by semi-qRT-PCR for *GLUT1*, *HK1*, *HK2*, *PKM2*, and *LDHA*. (B) Inhibition of TTP by siRNA increases *HK2* expression in cancer cells. MCF-7 and A549 cells were transiently transfected with TTP-specific siRNA or scRNA for 24 h. Cells were analyzed by semi-qRT-PCR for *GLUT1*, *HK1*, *HK2*, *PKM2*, and *LDHA*. (C, D) TTP destabilizes *HK2* mRNAs in cancer cells. MDAMB231 and H1299 cells were transiently transfected with pcDNA6/V5-TTP or pcDNA6/V5 for 24 h. Expression of (C) *GLUT1*, *HK1*, *PKM2*, *LDHA* and (D) *HK2* in cells was determined by qRT-PCR at indicated times after addition of 5 μg/ml actinomycin D. mRNA half-life was calculated from the nonlinear regression of the mRNA levels at the indicated times after addition of actinomycin D. Data are mean *±* SD (*n* = 3; \*\**p \<* 0.01; \*\*\**p \<* 0.001). (E) TTP overexpression does not affect expression of *BAG3*, *Imp3*, and *Roquin* in cancer cells. MDAMB231 and H1299 cells were transiently transfected with pcDNA6/V5-TTP or pcDNA6/V5 for 24 h. Cells were analyzed by semi-qRT-PCR for *BAG3*, *Imp3*, and *Roquin*.](mbc-30-542-g003){#F3}

TTP decreases expression of luciferase mRNA containing the *HK2* 3′-UTR
-----------------------------------------------------------------------

Analysis of the 2429--base pair human *HK2* 3′-UTR revealed three pentameric AUUUA ARE motifs ([Figure 4A](#F4){ref-type="fig"}). To determine whether down-regulation of *HK2* expression by TTP was mediated through the *HK2* mRNA 3′-UTR, we used a luciferase reporter gene linked to the full *HK2* 3′-UTR or a fragment containing all three AREs in the plasmid psiCHECK2. When MDAMB231 cells were transfected with plasmid to overexpress TTP, luciferase activity from the full ([Figure 4B](#F4){ref-type="fig"}) or fragment ([Figure 4C](#F4){ref-type="fig"}) *HK2* 3′-UTR was inhibited. To determine the AREs within *HK2* 3′-UTR that responded to TTP, we generated a luciferase reporter gene linked to oligonucleotides containing the first and second (oligo-ARE-1,2) or third AUUUA motif (oligo-ARE-3) in the plasmid psiCHECK2. Oligo-ARE-1,2 did not respond to TTP ([Figure 4D](#F4){ref-type="fig"}), but luciferase activity from oligo-ARE-3W was inhibited by TTP overexpression ([Figure 4E](#F4){ref-type="fig"}). To determine the importance of the third AUUUA motif, we prepared a luciferase reporter gene with mutant oligonucleotides (oligo-ARE-3M, containing AUUUA sequences substituted with AGCA). Oligo-ARE-3W responded to TTP but oligo-ARE-3M did not ([Figure 4E](#F4){ref-type="fig"}). Taken together, these results demonstrated that the third AUUUA motif in the *HK2* 3′-UTR was involved in TTP inhibition in MDAMB231 cells.

![ARE-3 within the *HK2* mRNA 3′-UTR is essential for reduction by TTP. (A) Schematic representation of luciferase reporter constructs used in this study. (B--E) The third pentameric AUUUA motif within the *HK2* 3′-UTR is necessary for reduction by TTP. Full-length (Full), fragment (Frag), and oligonucleotides (Oligo) from the 2429--base pair *HK2* 3′-UTR were cloned downstream of the luciferase reporter gene in the psiCHECK2 luciferase expression vector. White circles, wild-type (W) pentameric motif AUUUA; black circle, mutated (M) motif AGCA. MDAMB231 cells were cotransfected with pcDNA6/V5-TTP and psiCHECK2 luciferase reporter constructs containing (B) full-length, (C) fragment, (D) oligo-ARE-1,2, and (E) oligo-ARE-3W or oligo-ARE-3M. After normalization, luciferase activity from the MDAMB231 cells transfected with the psiCHECK2 vector alone was set to 1.0. Data are mean *±* SD (*n* = 3; \*\**p \<* 0.01; \*\*\**p \<* 0.001; ns, not significant). (F) Ribonucleoprotein immunoprecipitation assays. MDAMB231 cells were cotransfected with pcDNA6/V5-TTP and psiCHECK2 luciferase reporter constructs containing *HK2* oligo-ARE-1,2 or oligo-ARE-3W. The psiCHECK2 luciferase reporter construct containing mutant ARE-3, oligo-ARE-3M was the negative control. At 48 h after transfection, ribonucleoprotein complexes containing TTP were immunoprecipitated with protein G-agarose and anti-V5 or control antibody. Luciferase mRNA in immunoprecipitates was amplified by semi-qRT-PCR. TTP in immunoprecipitates was detected by Western blot with anti-V5. (G) TTP destabilizes luciferase reporter mRNA containing *HK2* oligo-ARE-3W but not *HK2* oligo-ARE-3M or *HK2* oligo-ARE-1,2. MDAMB231 cells were transiently cotransfected with pcDNA6/V5-TTP and psiCHECK2 luciferase reporter constructs containing fragment, oligo-ARE-1,2, oligo-ARE-3W, or oligo-ARE-3M for 24 h. Expression of luciferase reporter in cells was determined by qRT-PCR at indicated times after addition of 5 μg/ml actinomycin D. mRNA half-life was calculated from the nonlinear regression of the mRNA levels at the indicated times after addition of actinomycin D. Data are mean *±* SD (*n* = 3; \*\**p \<* 0.01).](mbc-30-542-g004){#F4}

TTP binds to the third ARE motif, ARE-3, in the *HK2* mRNA 3′-UTR
-----------------------------------------------------------------

To determine whether TTP interacted with ARE-1,2 or ARE-3 of the *HK2* 3′-UTR, MDAMB231 cells were cotransfected with pcDNA6/V5-TTP and psiCHECK2-oligo-ARE-3W (oligo-ARE-3W), psiCHECK2-oligo-ARE-3M (oligo-ARE-3M), or psiCHECK2-oligo-ARE-1,2 (oligo-ARE-1,2). After immunoprecipitation with anti-V5 or control antibody (immunoglobulin G), the presence of TTP was determined by Western blots using anti-V5 ([Figure 4F](#F4){ref-type="fig"}, bottom). Total RNA was extracted from immunoprecipitates, and the presence of luciferase mRNA was analyzed by RT-PCR using PCR primers specific to the luciferase gene. Amplified PCR product was observed in immunoprecipitates from cells cotransfected with oligo-ARE-3W and pcDNA6/V5-TTP ([Figure 4F](#F4){ref-type="fig"}, top). No PCR products were detected in samples from cells cotransfected with pcDNA6/V5-TTP and oligo-ARE-3M or oligo-ARE-1,2 ([Figure 4F](#F4){ref-type="fig"}, top). PCR product was also not detected in immunoprecipitates obtained using control antibody. We also determined the effect of TTP overexpression on mRNA degradation of the luciferase reporter genes linked to *HK2* AREs in MDAMB231 cells. TTP overexpression enhanced the mRNA degradation of reporter genes linked to a fragment containing all three AREs or ARE-3W of *HK2* but did not affect the mRNA stability of luciferase reporter genes linked to *HK2* ARE-3M or ARE-1,2 ([Figure 4G](#F4){ref-type="fig"}). These results demonstrated that TTP interacted specifically with *HK2* ARE-3 and enhanced degradation of *HK2* ARE-3-containing mRNA.

TTP reduces hexokinase activity of cancer cells
-----------------------------------------------

HK2 is a key enzyme in the phosphorylation of glucose in glycolysis in cancer cells ([@B29]). We determined the effects of TTP expression on hexokinase activity. Expression of HK2 correlated negatively with TTP in cancer cells: expression of HK2 in MDAMB231 and H1299 cells, which had low TTP, was higher than in MCF-7 and A549 cells, which had high TTP ([Figure 5A](#F5){ref-type="fig"}). Overexpression of TTP in MDAMB231 and H1299 cells ([Figure 5B](#F5){ref-type="fig"}) reduced hexokinase activity ([Figure 5C](#F5){ref-type="fig"}). Inhibition of *TTP* by siRNA (TTP-siRNA; [Figure 5D](#F5){ref-type="fig"}) enhanced hexokinase activity in MCF-7 and A549 cells ([Figure 5E](#F5){ref-type="fig"}). These results suggested that TTP expression reduced hexokinase activity in cancer cells.

![TTP reduces hexokinase activity in cancer cells. (A) Expression of HK2 negatively correlates with TTP in cancer cells. MDAMB231, MCF-7, H1299, and A549 cells were analyzed for TTP and HK2 by semi-qRT-PCR (top) and Western blot (bottom). (B, C) Overexpression of TTP decreases hexokinase activity in cancer cells. MDAMB231 and H1299 cells were transiently transfected with 1 μg pcDNA6/V5-TTP (MDAMB231/TTP) or pcDNA6/V5 (MDAMB231/pcDNA) for 24 h. Cells were analyzed for expression of TTP and HK2 by semi-qRT-PCR (top) and Western blot (bottom) (B) and for hexokinase activity (C). Data represent three experiments and are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01). (D, E) Inhibition of *TTP* by siRNA increases hexokinase activity in cancer cells. MCF-7 and A549 cells were transfected with scRNA or TTP-specific siRNA (TTP-siRNA) for 24 h. Cells were analyzed for expression of TTP and HK2 by semi-qRT-PCR (top) and Western blot (bottom) (D) and for hexokinase activity (E). Data represent three experiments and are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01).](mbc-30-542-g005){#F5}

Ectopic expression of *HK2* attenuates reduction of glycolysis by TTP
---------------------------------------------------------------------

On the basis of our results, we hypothesized that TTP controlled the glycolytic capacity of cancer cells by down-regulation of HK2. To test this, we cotransfected MDAMB231 and H1299 cells with pcDNA6/V5-TTP and FLHKII-pGFPN3, which did not contain *HK2* 3′-UTR. At 24 h after transfection, cells were analyzed for glycolytic capacity. Expression of *HK2* ([Figure 6A](#F6){ref-type="fig"}) significantly abrogated reduction by TTP of hexokinase activity ([Figure 6B](#F6){ref-type="fig"}), glucose uptake ([Figure 6C](#F6){ref-type="fig"}), and production of glucose-6-phosphate (G-6-P; [Figure 6D](#F6){ref-type="fig"}), pyruvate ([Figure 6E](#F6){ref-type="fig"}), and lactate ([Figure 6F](#F6){ref-type="fig"}). These results indicated that TTP suppressed glycolytic capacity through down-regulation of HK2 in cancer cells.

![Overexpression of *HK2* attenuates reduction of glycolytic capacity of cancer cells by TTP. MDAMB231 and H1299 cells were transiently transfected with empty vector pcDNA6/V5 or pcDNA6/V5-TTP and FLHKII-pGFPN3 for 48 h. (A) TTP and HK2 levels were determined by RT-PCR (top) and Western blot (bottom). Cells were analyzed for (B) hexokinase activity, (C) glucose uptake, (D) G6P, (E) pyruvate production, and (F) lactate production. Data are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).](mbc-30-542-g006){#F6}

TTP overexpression reduces extracellular acidification, oxygen consumption rates, ATP levels, and cell proliferation
--------------------------------------------------------------------------------------------------------------------

Glycolysis is determined by measuring the extracellular acidification rate (ECAR) of media surrounding cells. Acidification is predominantly from excretion of lactic acid over time after conversion from pyruvate ([@B45]). To evaluate the glycolytic phenotype, control and TTP-overexpressing cells were subjected to Seahorse Extracellular Flux Analysis to assess cellular bioenergetic activity. Results from glucose stress tests indicated that TTP overexpression significantly decreased ECAR associated with glycolysis, glycolytic capacity, and glycolytic reserve in MDAMB231 and H1299 cells ([Figure 7, A and B](#F7){ref-type="fig"}). TTP overexpression also altered mitochondrial respiration using Seahorse Mito stress tests. Oxygen consumption rates (OCRs) associated with basal and maximal mitochondrial respiration were significantly down-regulated in TTP-overexpressing MDAMB231 and H1299 cells ([Figure 7, C and D](#F7){ref-type="fig"}). Ectopic expression of *HK2* abrogated reduction of ECAR and OCR by TTP in both MDAMB231 and H1299 cells ([Figure 7, A--D](#F7){ref-type="fig"}). We investigated ATP content and cell proliferation of TTP-overexpressing cells. Consistent with the decrease in ECAR and OCR, significant decreases in ATP content and cell proliferation were observed in TTP-overexpressing MDAMB231 and H1299 cells ([Figure 7, E and F](#F7){ref-type="fig"}). Ectopic expression of HK2 rescued the ATP content and cell proliferation in TTP-overexpressing MDAMB231 and H1299 cells ([Figure 7, E and F](#F7){ref-type="fig"}). Taken together, these results demonstrated that overexpression of TTP reduced expression of HK2, followed by decreased glycolysis, mitochondrial respiration, ATP production, and cell proliferation in cancer cells.

![TTP overexpression decreases extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) and ectopic expression of *HK2* attenuates TTP reduction of OCR and ECAR in cancer cells. MDAMB231 and H1299 cells were transiently transfected with empty vector pcDNA6/V5 or pcDNA6/V5-TTP and FLHKII-pGFPN3 for 48 h. (A--D) TTP overexpression decreases both ECAR and OCR in cancer cells. Mean ECAR in transiently transfected MDAMB231 cells (A) and H1299 cells (B) was measured before and after sequential addition of glucose (1 μM), oligomycin (1 μM), and 2-DG (1 μM). Each data point represents an ECAR measurement. Graphs show glycolysis, glycolytic capacity, and glycolytic reserve. Data are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01). Mean OCR of transfected MDAMB231 cells (C) and H1299 cells (D) before and after addition of oligomycin (1 μM), FCCP (1 μM), or antimycin A (1 μM). Each data point represents an OCR measurement. Graphs are basal respiration, proton leak, and ATP production. Data are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01). (E) TTP overexpression decreases cellular ATP levels in cancer cells. Cellular ATP from transfected MDAMB231 and H1299 cells, measured using the luminescent cell viability assays. Data are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001). (F) TTP overexpression inhibits proliferation of cancer cells. Proliferation of transfected MDAMB231 and H1299 cells was assessed as absorbance at 490 nm using MTS cell proliferation assays. Graphs show relative cell proliferation. Data are mean ± SD (*n* = 3; \**p* \< 0.05; \*\**p* \< 0.01).](mbc-30-542-g007){#F7}

DISCUSSION
==========

HK2 is a key enzyme that catalyzes the rate-limiting first step of glycolysis and is highly up-regulated in multiple human tumors ([@B9]). Here, we demonstrated that TTP acts as a key regulator of *HK2* expression and glycolysis in cancer cells. We provided evidence that *HK2* was a target of TTP: the *HK2* mRNA 3′-UTR contained an ARE, TTP decreased expression of a luciferase reporter gene linked to the *HK2* mRNA 3′-UTR, TTP bound to the *HK2* mRNA 3′-UTR, and overexpression of TTP enhanced degradation of *HK2* mRNA and decreased expression of HK2 in cancer cells. In addition, we found that TTP overexpression decreased glycolytic capacity. Ectopic expression of *HK2* abrogated reduction of the glycolytic capacity of cancer cells by TTP. Thus, our data indicated that TTP acted as a negative regulator of glycolysis through posttranscriptional down-regulation of *HK2* in cancer cells.

Four isoforms, HK1--HK4, are found in mammalian HKs ([@B43]). Among these, HK2 is the predominantly overexpressed form in multiple human tumors ([@B9]) and is essential for cancer growth, survival, and metastasis ([@B29]). We investigated the underlying mechanisms of increased expression of HK2 in tumors. Tumors use a multitude of genetic, epigenetic, transcriptional, and posttranslational strategies to enhance HK2 expression ([@B26]). During tumorigenesis, the *HK2* gene is switched on by demethylation of the *HK2* gene promoter ([@B10]). The *HK2* promoter contains well-defined cis-elements for transcription initiation (TATA and CAAT) and for activation by protein kinase-A and protein kinase-C pathways ([@B27]; [@B32]; [@B19]). In addition, functional response elements for hypoxia via HIF-1 and p53 are located in the HK2 promoter ([@B25], [@B28]). Response elements in the proximal region of the *HK2* promoter required for its activity are either absent or poorly conserved in the promoters of *HK1*, *HK3*, and *HK4* ([@B19]). Roquin ([@B1]) and several miRs such as miR-199a-5p ([@B11]), miR-4458 ([@B31]), and miR-143 ([@B9]; [@B30]) are reported to target *HK2* mRNA and down-regulate HK2 expression. Although these findings help explain the selective expression of *HK2* in cancer cells, they are not sufficient to explain the enhanced expression of *HK2* in cancer cells, because these regulations may not occur only in tumor cells. In this study, we demonstrated that *HK2*, but not *HK1*, contains an ARE within its mRNA 3′-UTR. Thus, TTP reduced the expression of *HK2* but not *HK1* in human cancer cells. It has been reported that TTP expression is substantially decreased in 65% of human tumors derived from 19 different tissues and with particularly high frequency in tumors of the thyroid, lung, ovary, uterus, and breast ([@B4]). Considering that TTP acts as a negative regulator of HK2 expression in cancer cells, down-regulation of TTP in human tumors would critically contribute to up-regulation of HK2 and the Warburg effect in cancer cells.

HK2 binds to voltage-dependent anion channels (VDACs) on the outer mitochondrial membrane ([@B34]; [@B42]) and preferentially accesses and uses mitochondrially generated ATP to phosphorylate glucose to glucose-6-phosphate ([@B2]). HK binding to VDACs is proposed to suppress mitochondrial function while stimulating glycolysis ([@B20]). This proposal was in a report suggesting that inhibition of HK2 activity leads to a switch in bioenergetics from aerobic glycolysis to mitochondrial oxidative phosphorylation ([@B21]). However, whether HK2 suppresses mitochondrial oxidative phosphorylation is controversial. Dissociation of HK2 from mitochondria is reported to inhibit glycolysis and mitochondrial respiration and deplete intracellular ATP levels ([@B44]). Consistent with these findings, we found that down-regulation of *HK2* by TTP decreased both the oxygen consumption rate, mediated by mitochondria, and the glycolytic capacity of cancer cells. In addition, TTP overexpression decreased intracellular ATP in cancer cells. We previously reported that TTP induces mitochondrial dysfunction through down-regulation of α-synuclein ([@B40]). Thus, we hypothesize that even though we did not determine the effect of TTP overexpression on α-synuclein level, TTP overexpression might inhibit mitochondrial oxidative phosphorylation through down-regulation of α-synuclein. We found that ectopic expression of HK2 rescued OCR and ECAR in TTP-overexpressed cancer cells, indicating that inhibition of mitochondrial oxidative phosphorylation and glycolysis by TTP was mediated by HK2 down-regulation. Collectively, our data suggested that TTP reduced both mitochondrial oxidative phosphorylation and glycolysis through down-regulation of HK2 in cancer cells.

In this study, we found that the expression of *Glut1* and *LDHA* was induced by TTP inhibition. It is not likely that these genes are direct targets of TTP since TTP overexpression did not affect their mRNA stability. Glycolytic genes including *Glut1* and *LDHA* are induced by HIF-1α ([@B36]), whose expression and activity are modulated by mitochondrial dysfunction ([@B7]; [@B23]). Considering that TTP can induce mitochondrial dysfunction ([@B40]), it is possible that TTP may indirectly regulate the expression of *Glut1* and *LDHA* by inducing mitochondrial dysfunction.

In conclusion, our data suggested that TTP reduced both glycolysis and mitochondrial energy generation of human cancer cells through destabilization of *HK2* mRNA. We demonstrated that TTP enhanced degradation of *HK2* mRNA through binding to an AUUUA motif in the *HK2* mRNA 3′-UTR. *HK1* mRNA did not contain an AUUUA motif within its 3′-UTR. Thus, its expression was not regulated by TTP. Since TTP expression is inhibited in a variety of human cancer cells ([@B4]), HK2 up-regulation in cancer cells could be considered a consequence of low TTP levels in cancer. This study provided a molecular mechanism for the enhanced levels of *HK2* in cancer cells. TTP-mediated enhancing of *HK2* mRNA degradation expands our understanding of the regulation of *HK2* expression in cancer cells.

MATERIALS AND METHODS
=====================

Cell culture
------------

The human cancer cell lines MDAMB231, H1299, MCF-7, and A549 were from the Korean Cell Line Bank (KCLB-Seoul, Korea). MDAMB231 cells were cultured in DMEM. H1299, MCF-7, and A549 cells were cultured in RPMI media. All cell lines were supplemented with 10% FBS (heat-inactivated fetal bovine serum; Welgene, Korea) and were maintained at 37°C under a humidified atmosphere of 5% CO~2~.

Plasmids, small interfering RNAs, transfections, and dual-luciferase assays
---------------------------------------------------------------------------

The pcDNA6/V5-TTP construct was described previously ([@B17],[@B18]). The FLHKII-pGFPN3 construct (Hossein Ardehali, Northwestern University) was from Addgene. MDAMB231 and H1299 cells were transfected with pcDNA6/V5-TTP or FLHKII-pGFPN3 using the TurboFect in vitro transfection reagent (R0531; Thermo Scientific).

siRNAs against human *TTP* (*TTP*-siRNA, sc-36760) and control siRNA (scRNA, sc-37007) were from Santa Cruz Biotechnology (Santa Cruz, CA). MCF-7 and A549 cells were transfected 24 h after plating using Lipofectamine RNAiMAX (13778-150; Invitrogen) and harvested at 48 h. Expression of TTP or HK2 mRNA and protein was analyzed by RT-PCR and Western blots.

A full-length version and a fragment of *HK2* 3′-UTR containing all three pentameric AUUUA motifs were amplified from MDAMB231 cDNA using the PCR primers HK2-3′-UTR Full-U, 5′-CCG[CTCG­AG]{.ul}AACCCCTGAAATCGGAAGGG-3′; HK2-3′-UTR-Full-D, 5′-ATAAGAAT[GCGGCCGC]{.ul}ATTTTGGAAAATGTTAAAAT-3′; HK2-3′-UTR-Frag-U, 5′-CCG[CTCGAG]{.ul}GTTTTACAAATTTTTCCTGC-3′; and HK2-3′-UTR-Frag-D, 5′-ATAAGAAT[GCGGCCGC]{.ul}CTGCCCTTTAACTACACTGA-3′. Underlined sequences are restriction enzyme sites. PCR products were inserted into the *Xho*I/*Not*I sites of the psiCHECK2 Renilla/Firefly dual-luciferase expression vector (Promega) to generate psiCHECK2-HK2 3′-UTR-Full and psiCHECK2-HK2 3′-UTR-Frag. Two oligonucleotides containing the first and the second pentameric AUUUA motifs (oligo-ARE-1,2) and the third pentameric AUUUA motif (oligo-ARE-3) of the *HK2* mRNA 3′-UTR were synthesized by ST Pharm (Korea; [Table 1](#T1){ref-type="table"}). Oligonucleotides were inserted into the *Xho*I/*Not*I sites of the psiCHECK2 expression vector. A mutant oligonucleotide with the AUUUA pentamer in the third AUUUA motif replaced with AGCA (oligo-ARE-3M) was also synthesized and ligated into the *Xho*I/*Not*I site of psiCHECK2. For luciferase assays, cells were cotransfected with indicated psiCHECK2-HK2 3′-UTR constructs and pcDNA6/V5-TTP using the TurboFect in vitro transfection reagent (R0531; Thermo Scientific). Transfected cells were lysed with lysis buffer and mixed with luciferase assay reagent (017757, Promega). Chemiluminescence signal was measured using a SpectraMax L microplate reader (Molecular Devices). Firefly luciferase was normalized to Renilla luciferase for each sample. Luciferase assays represent at least three independent experiments, each of three wells per transfection.

###### 

Oligonucleotides used to analyze *HK2* mRNA 3′-UTR.

  ----------------------------------------------------------------------------------------------------------------------------------
  Oligonucleotides   Sequences
  ------------------ ---------------------------------------------------------------------------------------------------------------
  Oligo-ARE-1,2      F: 5′-[TCGAG]{.ul}TGGAATCACTGTATTTTCATTTTA**ATTTA**TATTTGAAATTTT**ATTTA**GTTCTTGATAGATCTGCTT­CTTC[GC]{.ul}-3′

                     R: 5′-[GGCCGC]{.ul}GAAGAAGCAGATCTACTCAAGAAC**TAAAT**AAAATTTCAAATA**TAAAT**TAAAATGAAAATACAGTGATTCCA[C]{.ul}-3′

  Oligo-ARE-3W       F: 5′-[TCGAG]{.ul}TGAATGGTCAGTTGTACGTAATTGT**ATTTA**TATGTTAATTTGTTATGTATATAG[GC]{.ul}-3′

                     R: 5′-[GGCCGC]{.ul}CTATATACATAACAAATTAACATA**TAAAT**ACATT\
                     ACGTACAACTGACCATTCA[C]{.ul}-3′

  Oligo-ARE-3M       F: 5′-[TCGAG]{.ul}TGAATGGTCAGTTGTACGTAATTGT**AGCA**TATGTTAATTTGTTATGTATATAG[GC]{.ul}-3′

                     R: 5′-[GGCCGC]{.ul}CTATATACATAACAAATTAACATA**TGCT**ACATTA\
                     CGTACAACTGACCATTCA[C]{.ul}-3′
  ----------------------------------------------------------------------------------------------------------------------------------

Underlined sequences are restriction enzyme sites. Bold sequences are wild-type and mutant AU-rich elements.

SDS--PAGE analysis and immunoblotting
-------------------------------------

Proteins were resolved by SDS--PAGE, transferred to nitrocellulose membranes (10600001; GE Healthcare), and probed with appropriate dilutions of anti-TTP (SAB4200505; Sigma), anti-HK2 (\#2837; Cell Signaling), and anti--β-actin (A5441; Sigma). Immunoreactivity was detected using an ECL detection system (GE Healthcare). Films were exposed at multiple time points to ensure that images were not saturated. If required, band densities were analyzed with National Institutes of Health image software and normalized by comparison with densities of internal control β-actin bands.

RNA kinetics, quantitative real-time PCR, and semiquantitative RT-PCR
---------------------------------------------------------------------

For RNA kinetic analysis, we used actinomycin D (A9415; Sigma) and assessed *HK2* mRNA expression using quantitative real-time PCR (qRT-PCR). DNase I--treated total RNA (2 µg) was reverse-transcribed using oligo-dT (79237; Qiagen) and MMLV reverse transcriptase (3201; Beamsbio) according to the manufacturer's instructions. qRT-PCR was performed by monitoring increased fluorescence in real-time with the SYBR Green dye (MasterMix-R; Abm) using the StepOnePlus real-time PCR system (Applied Biosystems). Semiquantitative RT-PCR (semi-qRT-PCR) used Taq polymerase 2X premix (Solgent) and appropriate primers. PCR primer pairs were TTP, 5′-CGCTACAAGACTGAGCTAT-3′ and 5′-GAGGTAGAACTTG­TGACAGA-3′; HK2, 5′-GGTGGACAGGATACGAGAAAAC-3′ and 5′-ACATCACATTTCGGAGCCAG-3′; GLUT1, 5′-CTTCACTGTCGTGTCGCTGT-3′ and 5′-TGAAGAGTTCAGCCACGATG-3′; HK1, 5′-TACTTCACGGAGCTGAAGGATG-3′ and 5′-CACCCGCAGA­ATTCGAAAGG-3′; PKM2, 5′-CTATCCTCTGGAGGCTGTGC-3′ and 5′-CCAGACTTGGTGAGGACGAT-3′; LDHA, 5′-GAGGTTCACAA­GCAGGTGGT-3′ and 5′-CCCAAAATGCAAGGAACACT-3′; and GAPDH, 5′-ACATCAAGAAGGTGGTGAAG-3′ and 5′-CTGTTGCTGTAGCCAAATTC-3′. mRNA half-life was calculated by nonlinear regression of mRNA at 30-, 60-, 90-, and 120-min timepoints following addition of actinomycin D using GraphPad Prism 5.00 software based on a one-phase exponential decay model.

Ribonucleoprotein immunoprecipitation assays
--------------------------------------------

To determine binding of TTP to *HK2* ARE, ribonucleoprotein immunoprecipitation (RNP) assays were conducted as described previously ([@B18]): MDAMB231 cells (1 × 10^7^) were cotransfected with 10 μg pcDNA6/V5-TTP and psiCHECK2-HK2-oligo-ARE-3W or psiCHECK2-HK2-oligo-ARE-3M. At 24 h after transfection, cell suspensions were incubated in 1% formaldehyde for 20 min at room temperature. Reactions were stopped with 0.25 M glycine (pH 7.0), and cells were sonicated in modified radioimmune precipitation assay buffer containing protease inhibitors (Roche Applied Science). RNP complexes were immunoprecipitated using protein G-agarose beads preincubated with 1 μg anti-V5 Tag antibody (GWB-7DC53A, Genway Biotech) or 1 μg isotype control (Sigma). After cross-link reversion at 70°C for 45 min, RNA was isolated from immunoprecipitates and treated with DNase I (Qiagen). From the RNA, cDNA was synthesized, and the Renilla luciferase gene was amplified by PCR using *Taq* polymerase and Renilla luciferase-specific primers (Up, 5′-ACGTGCTGGACTCCTTCATC-3′; and Down, 5′-GACACTCTCA­GCATGGACGA-3′). TTP proteins in immunoprecipitated samples were detected by Western blot using anti-V5 Tag.

Cell proliferation
------------------

Cells were transfected with a combination of pcDNA6/V5-TTP and FLHKII-pGFPN3 for 48 h. Cells were seeded in triplicate in 96-well culture plates at 5 × 10^3^ cells/well and incubated for 24 h. Cells were measured with CellTiter 96 AQueous One Solution cell proliferation assays (Promega, 3580) according to the manufacturer's instructions, and absorbance at 490 nm was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

ATP assays
----------

Cellular ATP levels were measured using CellTiter-Glo luminescent cell viability assay kits (G7570; Promega) according to the manufacturer's instructions. MDAMB231 and H1299 cells were plated on 96-well white-walled plates with clear bottoms in 100 μl culture medium, and 100 μl CellTiter-Glo reagent was added to each well. Contents were mixed for 2 min on an orbital shaker to induce cellular lysis, followed by incubation at room temperature for 10 min to stabilize the signal. Luminescence was recorded immediately.

Glucose-6-phosphate assays
--------------------------

Glucose-6-phosphate (G6P) was measured using glucose-6-phosphate assay kits (MAK014; Sigma) according to the manufacturer's instructions: cells (1 × 10^6^) were homogenized in two volumes of ice-cold PBS. After centrifugation at 13,000 × *g* for 10 min to remove insoluble materials, 50 μl of supernatant was added to duplicate wells of 96-well plates. After addition of 50 μl reaction mix containing G6P Assay Buffer, G6P Enzyme Mix, and G6P Substrate Mix, absorbance at 450 nm was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

Hexokinase assays
-----------------

Hexokinase activity was measured using hexokinase colorimetric assay kits (MAK091, Sigma) according to the manufacturer's instructions: cells (1 × 10^6^) were homogenized in 200 μl of ice-cold HK Assay Buffer. After centrifugation at 13,000 × *g* for 10 min to remove insoluble materials, 50 μl supernatant was added to duplicate wells of 96-well plates. After addition of 50 μl reaction mix containing HK Assay Buffer, HK Enzyme mix, HK Developer, HK Coenzyme, and HK Substrate, absorbance at 450 nm was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

Pyruvate assays
---------------

Pyruvate production was measured using pyruvate assay kits (MAK071; Sigma) according to the manufacturer's instructions: cells (1 × 10^6^) were homogenized in four volumes Pyruvate Assay Buffer. After centrifugation at 13,000 × *g* for 10 min to remove insoluble materials, 50 μl of supernatant was added to duplicate wells of 96-well plates. After addition of 50 μl reaction mix containing Pyruvate Assay Buffer, Pyruvate Probe Solution, and Pyruvate Enzyme Mix, absorbance at 570 nm was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

Lactate assays
--------------

Lactate production was measured using lactate assay kits II (MAK065; Sigma) according to the manufacturer's instructions: cells (1 × 10^6^) were homogenized in four volumes of Lactate Assay Buffer. After centrifugation at 13,000 × *g* for 10 min to remove insoluble materials, 50 μl of supernatant was added to duplicate wells of 96-well plates. After addition of 50 μl reaction mix containing Lactate Assay Buffer, Lactate Enzyme Mix, and Lactate Substrate Mix, absorbance at 450 nm was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

Glucose uptake assays
---------------------

Glucose uptake was determined using Glucose Uptake-Glo assays (J1342; Promega) according to the manufacturer's instructions: cells (1.5 × 10^4^) were seeded in wells of 96-well plates. After being washed with 100 µl PBS, cells were incubated with 50 µl 1 mM 2-deoxyglucose (2DG) per well for 10 min at room temperature. Cells were treated with 25 µl Stop Buffer, 25 µl Neutralization Buffer, and 100 µl 2-deoxyglucose-6-phosphate (2DG6P) Detection Reagent for 30 min at room temperature. Luminescence intensity was determined for each well using a Victor 1420 Multilabel Counter (EG&G Wallac, Turku, Finland).

Seahorse extracellular flux analysis
------------------------------------

Glycolysis and mitochondrial stress tests were performed using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) according to the manufacturer's instructions. Cells were seeded at 1.5 × 10^4^ cells per well in XF96 cell culture microplates and incubated for 24 h to ensure attachment. To measure oxygen consumption, cells were equilibrated for 1 h in unbuffered XF assay medium supplemented with 25 mM glucose, 1 mM sodium pyruvate, 2 mM glutamax, 1× nonessential amino acids, and 1% FBS in a non-CO~2~ incubator. Mitochondrial processes were examined through sequential injections of oligomycin (1 μM), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; 1 μM), and rotenone (1 μM)/antimycin A (1 μM). Indices of mitochondrial function were calculated as basal respiration rate (baseline OCR-rotenone/antimycin A OCR), ATP production (basal respiration rate-oligomycin OCR), and proton leak (oligomycin OCR-rotenone/antimycin A OCR). To measure glycolysis and glycolytic capacity, cells were cultured for 2 h in the absence of glucose. Three sequential injections of [d]{.smallcaps}-glucose (1 μM), oligomycin (1 μM), and 2-deoxyglucose (500 mM) provided ECAR associated with glycolysis, maximum glycolytic capacity, and nonglycolytic ECAR. Glycolysis was defined as ECAR following the addition of [d]{.smallcaps}-glucose and maximum glycolytic capacity was defined as ECAR following the addition of oligomycin. ECAR following treatment with 2-deoxyglucose is associated with nonglycolytic activity.

Statistical analysis
--------------------

For statistical comparisons, *p* values were determined using Student's *t* test or one-way analysis of variance. A *p* value of \<0.05 was considered significant.
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